France's rising debt, fiscal deficits, and sluggish GDP growth weigh on EWQ ETF performance. See why we rate the ETF a sell ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...